SynthesisMolecular biology reports2026
Mesenchymal stem cell therapy and gut microbiota modulation in preclinical disease models: a systematic review with implications for hypertension.
Synthesis in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem/stromal cells (MSCs) have regenerative and immunomodulatory properties and may influence gut microbial responses. This systematic review synthesised preclinical evidence on MSC-associated gut-microbiota modulation and considered its implications for hypertension. PubMed, Scopus, Ovid MEDLINE, EBSCOhost Academic Search Elite and Web of Science were systematically searched. Eligible in vivo studies were synthesised according to PRISMA 2020, and risk of bias was assessed using the SYRCLE tool. Thirty-one studies were included. Among 27 studies reporting α-diversity, 11 described an increase, three a decrease, 11 no significant difference and two a change without a clear direction. Twenty-seven studies reported β-diversity outcomes, with heterogeneous evidence of between-group differences in community composition. Four studies assessed the Firmicutes-to-Bacteroidetes ratio: three reported a lower ratio and one a higher ratio after intervention. Three studies directly quantified short-chain fatty acids, five used direct metabolomics or targeted bile-acid profiling, 18 assessed gut-barrier outcomes and 27 assessed inflammatory or immune outcomes. Of 310 risk-of-bias judgements, 74.5% were unclear and 25.5% were low risk. Only one study used a pulmonary-hypertension model; none directly evaluated systemic hypertension. The findings indicate context-dependent microbial, metabolic, barrier and immune responses rather than a universal restoration pattern. Concurrent microbiota and host changes did not generally demonstrate causal mediation, and enrichment of taxa associated with short-chain fatty-acid production could not substitute for direct metabolite measurement. MSC-associated gut-microbiota modulation is biologically plausible and warrants targeted mechanistic investigation. However, the current preclinical evidence does not establish an antihypertensive effect, particularly in systemic hypertension.
Indexed as
Identifiers
42801345What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.